Ocubio, a pioneering pharmaceutical company focused on innovative eye care solutions, is excited to announce the launch of its first product, Qualified Autologous Serum Eye Drops (qASED).
Developed by a team with decades of experience in eye care innovation, this breakthrough formulation is the first of its kind validated for room temperature use.
Developed from the latest research at the renowned Bascom Palmer Eye Institute, the #1 eye hospital in the United States, qASED harnesses the power of the patient’s own serum, which contains vital growth factors, nutrients, and anti-inflammatory agents.
The launch of qASED marks a significant milestone for Ocubio, which aims to improve the quality of life for patients through innovative therapies. “We are thrilled to introduce qASED to the market,” said Dr. Alfonso L. Sabater, chief vision officer of Ocubio. “Our mission is to revolutionize eye care by providing safe, effective and fully validated patient-centered solutions, and qASED is a testament to that commitment.”
Backed by a strong pipeline of strategic partnerships, Ocubio is poised to bring this transformative therapy to thousands of patients each year, redefining the standard of care in the field.
For more information about Ocubio and its Qualified Autologous Serum Eye Drops, please visit ocubio.com or contact info@ocubio.com
About Ocubio
Ocubio is a forward-thinking pharmaceutical company dedicated to developing innovative treatments for ocular surface diseases. With a strong foundation in research and a commitment to patient care, Ocubio aims to lead the way in advanced eye care solutions.